Analysts Set Becton, Dickinson and Company (NYSE:BDX) PT at $211.44

Shares of Becton, Dickinson and Company (NYSE:BDX) have received an average rating of “Hold” from the eleven research firms that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $213.30.

BDX has been the topic of a number of recent research reports. Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Morgan Stanley upped their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Argus upped their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Finally, Wells Fargo & Company increased their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $187.27 on Monday. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a market capitalization of $53.68 billion, a P/E ratio of 33.68, a PEG ratio of 1.52 and a beta of 0.27. The business has a 50 day moving average price of $187.65 and a 200 day moving average price of $190.39. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same quarter in the prior year, the company earned $3.50 EPS. Becton, Dickinson and Company’s revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is currently 74.82%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at $881,077.23. This represents a 19.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,965 shares of company stock worth $551,536. Corporate insiders own 0.36% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in BDX. Vanguard Group Inc. raised its position in shares of Becton, Dickinson and Company by 15.4% in the 2nd quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock worth $5,565,182,000 after buying an additional 4,305,947 shares during the period. Norges Bank purchased a new position in shares of Becton, Dickinson and Company in the 2nd quarter worth $653,377,000. First Eagle Investment Management LLC raised its position in shares of Becton, Dickinson and Company by 59.2% in the 2nd quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock worth $1,513,421,000 after buying an additional 3,268,478 shares during the period. GQG Partners LLC purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter worth $689,833,000. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Becton, Dickinson and Company by 24.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock worth $1,466,613,000 after buying an additional 1,670,590 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.